Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Moreover, Merck has entered into a new licensing agreement with Jiangsu Hengrui Pharmaceuticals, granting it exclusive rights to develop and commercialize HRS-5346, an oral small molecule Lp(a ...

Furthermore, Merck has entered an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals to develop and commercialize HRS-5346, a cardiovascular drug candidate targeting elevated ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Merck inks a licensing deal worth nearly $2B with China’s Jiangsu Hengrui GSK has also entered into a collaboration with the UK Dementia Research Institute and Health Data Research UK to ...

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...

With ongoing inflation, economic uncertainty, and global tensions, more investors are looking for ways to protect […] (Bloomberg) -- Merck & Co. will pay as much as $2 billion for the rights to ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...